Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep, going to be all about the PH 3 data release from the looks of things. IF they can project a bit about the potential
revenue stream from the newly licensed compound, that would help as well..
Not going to listen this morn, just watch the markets reaction.. to what MIGHT be vs what has been..
Good luck..
PS: can't forget they 'need' a $ before the end of the 3rd qtr or a r/split comes into play.. (doesn't it)
Look at the link from Timberwolf, you will read in bolt that ONTARGET results are imminent
What email? I've checked their 10q, nothing like this in there...
Email this morning: Top line results expected to be imminent for company’s phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea
IMMINENT (not forthcoming anymore), what other hint do you want?
Headed to work....Hoping the best...Maybe premature...Today is a reinforcement of a lesson I thought,I had already learned...Don't hold a ticker going into Earnings lol/smh
GOT a LINK to the morning PR??
actually what I said was, its what they SAY that matters..
In the meantime, the MARKET is reacting.. So unless you can fix that, it does matter as a 'first reaction' to whatever they said since
I haven't seen the release yet myself..
Exactly....the low should have been met...wishing that I was entering now instead of holding thru now
EPS is -0,6 , better than the estimated EPS (-0,8)
Do you still let them scare you with some pre market manipulation on low volume? Come on
It's not for another hour yet. 8:30am est.
well I am a guessing they didn't say anything 'good' this morning?? 23.5 cents.. hmmm
Lets just hope they give the market a reason to believe they have crossed the rubicon
with the potential for increasing revenue and working towards profitability.
The biggest problem shareholders may face is the 60 cent 1 year target price. Its not 'much',
but can they say enough this morn to keep moving the goalpost towards that 60 cents, give wall street a reason
to move it higher.. TBD'd.. Good luck..
.30++ for today - would be very nice and would be a great start to show the upward trend?
Sounds idealistic....If it's Standard Earnings,I can't imagine that....I would think ,In the negative.... hopefully just a wee.bit....Its just 1 day,start getting back to the 30s by eow
It could as good as .42
They had a statistical error back in november, and they called in a statistic expert to solve the problem. That's why it takes time
8:30 am Earnings ..
They are gonna suck. June will be better
What time is the meeting ? AHs? Trying to find the darn time...
STROOOONG NOW GREEEEN / LET'S GOOOOO
Your welcome...
same here.. Learned the hard way, there is the 'perceived' timeline for things to happen, and then there is
REALITY.. and oft as not, they aren't working together ..
CRMD: been holding it seriously since around 2018. 2 CRLS on their manufacturer and its 4 years of delays.
and I would have rotated out, but just never knew when/IF unexpected news was going to happen.
Turns out it didn't.. but finally ready to run post fda approval of something that is expected to become the
Standard of Care for what it does.. (might want to take a look at it. Shares around $5.30 ro so, 1st target price is $12-14, longer
term, $20+
$JAGX red to green and now let`s gooooplease BOOOOOOOOOOOOOOOM
thanks timberwolf7 for your feedback on that. Too many short term plays have ended up being long term holds because something I thought would happen didn't and by the time that is evident the stock has dropped by 50%. Trying to avoid that from now on.
My understanding is that the companies are in the 'dark' until the ones running the trial has completed its 'packaging' and informed the company.
What I don't know is if the ones running the trial tell the company WHEN that MIGHT happen or not.
Someone mentioned June, but I wouldn't be betting any 'short term' options on any date (I know Jagx doesn't offer options).
So if you are playing the PH 3 trial results, my experience is you sit back and wait to be 'surprised' with the announcement when it happens
Way its worked for me in all of my experiences with a trial release.. The only thing to add is, IF you are uncertain with respect to whether or
not the PH 3 can replicate the results of the PH 2, only bet what you can afford to lose.
Good luck
correct my rational is that is the posted end date of the trail. But honestly, they could decide to wait longer as well.
coming green soon ? looks good WEEEEEEEE
IMO Phase 3 results will not be released after June 1st.
For those that are familiar, is it likely they will say when the phase 3 results will be announced?
Uggg.26's ? Thought we'd see a run up today on Speculation?? And then the sell off on good news...Guess I'll buy some more
Guessing there are 'some' not sure of what tomorrow is going to bring, what they are going to say.
Suspect there are MOMENTUM TRADERS now bailing out at the last minute, getting out of the way of
tomorrow mornings CC.
and will say this, IF they don't say something 'good enough' to stimulate demand for the shares, I will be surprised
if the selling doesn't get ugly.. cause its pretty apparent, 'some' are expecting 'good news' and will be disappointed it
didn't come.. and they won't stick around..
Good luck
Lot of selling pressure this morn.. Did grab some at 27.8, thought of holding off for 27 cents.
Which doesn't sound like much, but does 'add' up.. But too much else to get done today to see if I can
scratch our a cent more (smile)... See if it can rebound to 30 cents..
Now a small positive hint about imminent approval or positive progress and the stock takes off.
imho
We should soon be moving into the green zone.
imo
Tad APPREHENSIVE this morning..
Had a shot at some shares sub 28 cents, seeing if I get another chance...
Institutional Ownership and Shareholders -Source: FINTEL (copyright)
Jaguar Health, Inc. (US:JAGX) has 28 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 4,669,694 shares. Largest shareholders include BlackRock Inc., Commonwealth Equity Services, Llc, Citadel Advisors Llc, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Vanguard Group Inc, Susquehanna International Group, Llp, Geode Capital Management, Llc, Csenge Advisory Group, Virtu Financial LLC, and FSMAX - Fidelity Extended Market Index Fund .
Jaguar Health, Inc. (NasdaqCM:JAGX) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%.
The share price as of May 10, 2024 is 0.29 / share. Previously, on May 12, 2023, the share price was 0.98 / share. This represents a decline of 70.19% over that period.
OVER .50 CENTS AFTER ANNUAL MEETING....GLTA!!!!!!!$$$$$$
Reverse split is delayed at least till end of July. They believe they can get the share price above 1 organically. That's why the Nasdaq hearing panel granted them an extension till August 13
Possible new share prices: $5 , $10, $20 , $30.all the way to $45.00 a share after Reverse Split. This will bring in many new deep pocket millionaires and many tutes like Black Rock loading up JAGX.
On April 9, 2024, the Company held a Special Meeting of Stockholders in order to, among other things, seek stockholder approval of an amendment to the Company’s COI to effect a reverse stock split of the Company’s issued and outstanding Common Stock at a ratio of not less than one-for-two (1:2) and not greater than one-for-one hundred and fifty (1:150), with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Board on or before January 22, 2025 without further approval or authorization of the Company’s stockholders (the “Proposed Reverse Stock Split”). The record date for the Annual General Meeting of Stockholders to which this proxy statement applies was May 13, 2024, prior to the effectiveness of any implementation of the Proposed Reverse Stock Split. Therefore, the disclosures in this proxy statement reflect share numbers outstanding prior to the effectiveness of the Proposed Reverse Stock Split.
BlackRock Inc. reports 4,974.35% increase in ownership of JAGX / Jaguar Health, Inc.
Board dead lately..
Interesting 🤔
Followers
|
151
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6874
|
Created
|
12/01/15
|
Type
|
Free
|
Moderators ProfitChaser oldstocks DTGoody crudeoil24 SmellMyFinger |
Jaguar Health, Inc. $JAGX
Bringing Plant-based Medicines to Life™
Pharmaceutical Manufacturing
San Francisco, California
Jaguar Health’s organizational framework is designed to enable our product pipeline to reach the world’s interconnected marketplace, allowing for development and commercialization opportunities worldwide.
Products:
Mytesi Crofelemer 125mg delayed release tablets
Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Market size of the FDA HIV Mytesi Crofelemer could be $25-$30 Million in the USA
Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea.
Mytesi is not indicated for the treatment of infectious diarrhea. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).
Canalevia-CA1 Crofelemer delayed release tablets
Distributors listed:
https://www.canalevia.com/distributor-information
CANALEVIA-CA1 is conditionally approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Lytham Partners Investor Select Conference February 1st, 2024
https://wsw.com/webcast/lytham10/jagx/2084640
Pipeline: https://jaguar.health/pipeline/
How to calculate the value of drugs and biotech companies
https://www.baybridgebio.com/drug_valuation.html
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study , a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative is focused on developing novel prescription medicines derived from plants for mental health indications.
A Case Report: Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea
Despite the efficacy of tyrosine kinase inhibitors (TKIs) across multiple cancers, side effects including treatment-related diarrhea can impede a patient’s ability to reach therapeutic doses or stay on therapy.
Below, we present the case of a 72-year-old patient with metastatic papillary renal cell carcinoma recurrent despite nephrectomy.
Over the course of treatment, the patient received multiple different tyrosine kinase inhibitors with varying efficacy.
Treatment with the TKI cabozantinib after failure of two prior TKIs resulted in a clinical response with shrinkage of his nodal metastatic disease.
However, the severe treatment-related diarrhea refractory to conventional management required both dose holds and dose reductions of cabozantinib.
Off-label administration of crofelemer, a novel FDA-approved antidiarrheal agent, successfully controlled the treatment-related diarrhea and allowed resumption and partial dose increase of cabozantinib.
This case suggests that crofelemer could be a viable therapeutic strategy to address TKI-induced diarrhea.
9.8 million people
receive chemotherapy worldwide per year
Wilson B, Jacob S, Yap M, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-780. doi:10.1016/S1470-2045(19)30163-9
Chemotherapy-induced
diarrhea occurs in
50%-80%
of treated patients
Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63. doi:10.1177/1758834009355164
Patients with cancer therapy–
related diarrhea (CTD) were
40% more likely to
discontinue chemotherapy or
targeted cancer therapy than
patients without CTD
Okhuysen PC, Schwartzberg LS, Roeland E, et al. The impact of cancer-related diarrhea on changes in cancer therapy patterns. J Clin Oncol. 2021;39(15):12111. doi:10.1200/JCO.2021.39.15_suppl.12111
Research & Development
In October 2020, Napo Pharmaceuticals initiated a pivotal Phase 3 clinical trial
This Phase 3 study is evaluating crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy
The principal investigator and co-investigators identified are from MD Anderson Cancer Center
Jaguar Health https://jaguar.health/
Napo Pharmaceuticals https://napopharma.com/
Napo Therapeutics https://napotherapeutics.com/en/
https://www.magdalenabiosciences.com/
Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.
Visit Jaguar on LinkedIn:
https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Phone: 415-371-8300
Contact: hello@jaguar.health
Press Releases: https://jaguarhealth.gcs-web.com/news-releases
Most if not all works by mechanism chloride ions into the gut then water comes and diarrhea out. Crofelemer normalizes abnormal ion flow targeting only locally in the gut.
Jaguar has been putting the expense into making sure Crofelemer drug supply is ready to get into this opportunity to treat cancer related chemo patients since pharmacy’s already can get FDA approved, all ready in the in the supply chain in the pharmacy as Crofelemer for AIDs patients.
Research has shown it costs 3x as much to treat a cancer patient with diarrhea.
It would be better to treat the cancer patient for diarrhea with Crofelemer pending OnTarget Study and FDA approval.
Since Crofelemer is FDA approved to treat dogs for Cancer Chemo related Diarrhea it has been said:
If your going to have cancer and cancer related Diarrhea, it’s better to be a dog than a human right now.
The companies that manufacture the cancer agents/drugs sort of point to the availability of Crofelemer because it allows them to keep their patients on their therapies thereby improving their penetration and their revenues opportunity.
3rd party market research put Short Bowel Syndrome at $5-$12 Billion opportunity because these patience are so ill, high mortality, high morbidity (the state of being unhealth for a particular disease or situation), so high of expense to manage through life.
That opportunity can be reached in small trials around the world to show benefits to be able to show global development.
Product already approved, already fully in the supply chain in the pharmacy.
Potential Market of Mytesi (crofelemer)
Jaguar and Napo $JAGX if the Phase 3 OnTarget Study has good results.
The Phase 3 OnTarget Study results are due to be out soon in this quarter.
The Phase 3 OnTarget study is testing whether the company's plant-based prescription drug crofelemer can prevent or substantially reduce diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies that are associated with diarrhea in patients is initiated.
Each year, more than 1 million cancer patients in the United States receive chemotherapy or radiation. Globally 9.8 million require chemotherapy.
Diarrhea is a common side effect of targeted therapies. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.
Any drug used to treat cancer (including tyrosine kinase inhibitors or TKIs) can be considered chemo, but here chemo is used to mean treatment with conventional cytotoxic (cell-killing) drugs that mainly kill cells that are growing and dividing rapidly. Chemo was once one of the main treatments for CML.
The cost for Mytesi oral delayed release tablet 125 mg is around $2,600 for a supply of 60 tablets. This amount is the one month supply as testing in the OnTarget Study.
That is a 24 week study = 5.6 month supply needed = $14,560.00 for treatment.
Potential Market of Mytesi (crofelemer)
100,000 patients a year = $1,456,000,000
250,000 patients a year = $3,640,000,000
500,000 patients a year = $7,280,000,000
1,000,000 patients a year = $14,560,000,000 (assuming worldwide)
5,000,000 patients a year = $72,800,000,000 (assuming worldwide)
The estimate of patients depends on how many quit taking chemo, the onTarget Study, FDA approval and or quit taking Mytesi (crofelemer).
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |